Meet the team at The World Vaccine Congress Europe! This award-winning series of conferences that have grown to become the largest and most established vaccine meetings across the globe. Our CEO Yamin 'Mo' Khan Khan, Chief Scientific Officer Andrew Catchpole, VP of Clinical Operations Adam French, Director of Laboratory Project Operations Alison Boyers, Senior Director of Business Development Rich Niemi & Director of Business Development Egle Pavyde will be attending this year's conference. 🤝 Schedule a meeting on the dedicated Terrapinn Events App or reach out via LinkedIn! 🔔Our Chief Scientific Officer will be presenting on Wednesday 30 October 2024 at 2:10pm, in Theatre 3. Learn more: https://lnkd.in/emYEjxf #HVO #WVC #WVCEU #Barcelona
hVIVO
Biotechnology Research
London, England 11,505 followers
The world leader in testing infectious and respiratory disease vaccines & therapeutics using human challenge trials.
About us
hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
- Website
-
http://www.hvivo.com
External link for hVIVO
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London, England
- Type
- Public Company
- Founded
- 1989
- Specialties
- clinical trials, uk clinical trials, clinical research, challenge models, human challenge models, human volunteer research, respiratory disease research, medical research, asthma studies, copd, influenza, human models of disease, clinical research, challenge studies, human challenge trials, RSV, malaria, HRV, Respiratory syncytial virus, Human rhinoviruse, lab services, and covid 19
Locations
-
Primary
40 Bank Street
London, England E14 5NR, GB
Employees at hVIVO
Updates
-
Our CEO Yamin 'Mo' Khan Mo Khan featured on the Gallagher Navigating Risk podcast back in June. Hosted by Helen Yates, Editor of Global Thought Leadership, Mo discusses the challenges that hVIVO faces in a highly regulated sector: ✅ Fully realising the potential in the UK Life Science Industry 👉 Regulations in human challenge trials 🔍 #HVO's unique market position ⬆️ COVID boosting the HCT profile 🦠 Preventing the next pandemic 🔬 Field Trials vs Human Challenge Trials Tune in here: https://lnkd.in/gkPscAqs #HumanChallenge #ScientificResearch #GallagherPodcast
Listen to the latest episode of our Navigating Risk podcast series where Mo Khan, Chief Executive Officer - hVIVO, discusses some of the challenges that they have been facing in the UK in recent years below https://lnkd.in/eqtRBVEV #InsuranceUK #Risk #CRO #Life #Science
-
We were featured among 8 other AIM-listed companies as an "exciting" company "that deserves a high valuation" in a recent UK Investor Magazine article. 🎯 £100m revenue target for 2028 📈 Revenue for H1 2024 rose 30% to £35.6m 🏙️ New state-of-the-art facility in Canary Wharf ✅ Record number of volunteers for challenge trials Read full article: https://lnkd.in/esaBbtxA #HVO #HCT #CHIM #UKInvestorMagazine #UKBudget
-
Our Head of QA Teja Marathe-Sarvadikar discusses how our new state-of-the-art facility at Canary Wharf benefits our quality assurance and compliance: 💼 Introduction to Teja and her role - providing regulatory support for Human Challenge Trials ✅ New facility ensuring maximum efficiency for our process flows 🏙️ What excites Teja most about Canary Wharf #HVO #QA #Regulatory #CHIM #HCT
-
Thanks to our hVIVO team for promoting & participating in some of the recent #ESG initiatives 🧁Bake sale in aid of Asthma + Lung UK 🎨 Social activities club at #CanaryWharf ☕ Macmillan Cancer Support Coffee Morning 🍰 Bake sale in aid of Galway Autism Partnership GAP Our social and community investment initiatives demonstrate our commitment to giving back and creating meaningful impacts beyond our corporate borders. #ESG #Charities #CharitableDonations #MacMillan #SocialClub
-
Congratulations to Enanta Pharmaceuticals on the positive topline results in the Phase 2a RSV human challenge trial for their antiviral product, EDP-323. The drug has been shown to be safe and effective using the challenge trial concept. hVIVO has already conducted over 30 RSV human challenge trials, we are pleased to add another success story to our portfolio. Learn more: https://lnkd.in/eTnvMD-w #HVO #RSV #ScientificResearch #HCT #RespiratoryVirus #CHIM
-
Meet with our Senior Director of Clinical Science Alexander Mann & Senior Director of Business Development Rich Niemi at this years IDWeek conference in Los Angeles. This conference provides the opportunity to discuss everything infectious disease related & attracts experts from across the globe. Our team looks forward to seeing you there! Learn more: https://idweek.org/ #IDWeek2024 #HVO #Conferences #InfectiousDisease
-
Check out the team at the OPTIONS XXI for the Control of Influenza Conference in Brisbane! Our team presented 6 scientific posters at the conference, showcasing hVIVO's extensive experience in #Influenza challenge studies & our new state-of-the-art facility in Canary Wharf. This conference has created a great space for sharing knowledge on #influenza clinical research, as well as networking with new and existing industry colleagues. #HVO #OPTIONSXII #Flu #ScientificResearch #CHIM #Australia #Brisbane
-
+1
-
Last week Investors' Chronicle published an opinion piece discussing how to revive the UK's small-cap sector. Both our CEO Yamin 'Mo' Khan and Chairman Cathal Friel were quoted and shared their insights. Read the full article here: https://lnkd.in/e5St-37x #HVO #UK #Investment
-
We have launched our full suite of hLAB standalone virology & immunology laboratory services for preclinical & clinical drug development. 🥼 hLAB - an industry leader in virology and clinical trial support 🔬 Providing laboratory services since 1989 ✅ New facility in Canary Wharf has tripled lab capacity 🦠 Cutting-edge CL-3 lab has received HSE clearance & is now operational 🧪Biobank services launched following approval by the UK Research Ethics Committee as a Research Tissue Bank Learn more: https://lnkd.in/eBjHfwg5 #HVO #hLAB #ClinicalResearch #ScientificResearch #Biobank #Labs #CanaryWharf